We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PIM

News List

Sanofi’s RSV treatment nirsevimab awarded PIM pharmatimes
January 22, 2021
Sanofi’s nirsevimab has been awarded a Promising Innovative Medicine (PIM) designation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for the prevention of respiratory syncytial virus (RSV) associated lower respiratory ...
Nirsevimab gets Promising Innovative Medicine Designation from MHRA expresspharma
January 19, 2021
Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus (RSV) infections in healthy late preterm, term and high-risk infants.
Akcea’s rare lipid disorder drug wins PIM status pharmatimes
October 11, 2017
Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome , a rare genetic lipid disorder.